Introduction

Several nutritional compounds are the focus of public attention because of their potential beneficial health effects. Some compounds derived from plants and herbs (e.g., Resveratrol, Curcumin) have been proven effective in traditional medicine as herbal remedies for inflammatory disorders such as hepatitis, arthritis, and colitis [1]. Both, Resveratrol and Curcumin also exert pharmacological effects in various experimental models of acute and chronic inflammation [1]. In addition, some pharmaceutical compounds (e.g., statins) have shown to possess anti-inflammatory, immuno-modulatory properties apart from their original indication for disease treatment [2].

Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a polyphenol found in grape skins and red wine. Resveratrol has been reported to exert multiple health-promoting benefits such as anti-inflammatory, anti-oxidant, anti-tumor, anti-platelet aggregation, anti-aging and anti-atherogenic effects [3]. Anti-inflammatory properties of Resveratrol have been described in several diseases such as arthritis [4], pancreatitis [5], and experimental colitis [6].

Curcumin is a polyphenol derived from the root of the turmeric plant Curcuma longa and responsible for the yellow-orange color and the spicy taste of curries [7]. Curcumin exerts anti-inflammatory, anti-tumor, and anti-inflammatory properties [8]. Preventive as well as therapeutic anti-inflammatory effects of Curcumin treatment have been observed in various animal models [9].

Simvastatin belongs to the class of cholesterol-lowering statins that are widely used to reduce cardiovascular morbidity and mortality in patients with or without coronary artery disease [10]. Statins have been also proposed to exert anti-inflammatory effects
that are not directly related to their cholesterol-lowering activity [2] by interfering with endothelial adhesion and leukocyte migration to sites of inflammation [11].

Within eight to ten days following peroral infection with the parasite Toxoplasma (T.) gondii, susceptible mice develop severe small intestinal necrosis (pan-ileitis), induced by IL-23 [12] and mediated by a strong Th1-type immune response with a subsequent storm of pro-inflammatory cytokines including IL-12, IFN-γ, TNF-α, and nitric oxide (NO) [13]. Furthermore, inflammation triggers characteristic quantitative as well as qualitative ileum flora shifts [14,15]. We demonstrated earlier that luminal concentrations of commensal Gram-negative bacteria such as E. coli increase and aggravate ileitis development through TLR4-dependent signaling pathways [15]. Moreover, commensal gut bacteria translocate through the leaky epithelial barrier into the intestinal submucosa and spread to adjacent organs through blood or lymphatic vessels leading to sepsis and multi-organ failure [12]. Taken together, the Th1-type immunopathology in the T. gondii-mediated ileitis model is triggered by the commensal microbiota and thus resembles the immunological key features of acute episodes in inflammatory bowel disease (IBD) such as Crohn’s disease (ileitis terminalis) in humans. However, experimental models of small intestinal inflammation are scarce and most of the experimental IBD models assess the large intestine. Given that Resveratrol, Curcumin or Simvastatin have been shown to suppress immune responses, we investigated the immuno-modulatory effects of these compounds in this well characterized model of ileitis. Our results showed the anti-inflammatory and immuno-modulating properties of all three compounds. Amelioration of ileitis was accompanied by reduced immunopathology and an integral gut barrier function that prevented bacterial translocation. These findings provide novel potential therapeutic options for patients during the acute episodes of Crohn’s disease.

**Results**

**Resveratrol treatment prolongs survival in an acute ileitis model**

To investigate the beneficial effects of Resveratrol, Curcumin, and Simvastatin on small intestinal inflammation, we infected C57BL/10 mice with T. gondii and compared survival rates between treated and Placebo control mice. Whereas all untreated control mice had died at day 11 p.i., 20% of Curcumin- and 40% of Simvastatin- or Resveratrol-treated animals survived the acute phase of inflammation (Fig. 1). Furthermore, Resveratrol treated mice displayed significantly higher survival rates until the end of the experiment as compared to Placebo controls (40% survival, 19 days post infection; p<0.005, Kaplan Meier analysis; Fig. 1). Thus, Resveratrol treatment prolongs survival in our hyper-acute ileitis model.

**Simvastatin, Curcumin, and Resveratrol ameliorate acute small intestinal inflammation**

Mice orally treated with Simvastatin, Resveratrol or Curcumin displayed significantly less macroscopic signs of intestinal inflammation. Within 8 days p.i., Placebo control mice had lost approximately 15% of their initial body weight whereas mice treated with either compound displayed significant less weight loss (between 9 and 11%; p<0.005) (Fig. 2 A). Given that ileal inflammation is accompanied by a significant shortening of the upper intestinal tract, we determined the lengths of the small intestine between treated and control animals. T. gondii infection resulted in less significant shortening of the small intestinal length in treated mice compared with the Placebo group (16–18% vs. 22% respectively; p<0.05) (Fig. 2 B). Moreover, animals treated with Simvastatin, Resveratrol or Curcumin displayed only mild signs of inflammation in their ileal mucosa including edema and cell-free exudate into the lumen but maintained an intact epithelium. In contrast, severe ileal inflammation including initial necrosis was observed in the control group (p<0.00001) (Fig. 2 C). Thus, oral treatment of Simvastatin, Resveratrol or Curcumin ameliorates acute small intestinal T. gondii-induced ileitis.

To examine whether differences in T. gondii loads within the ileum might have contributed to the beneficial effects observed after peroral treatment with Simvastatin, Resveratrol or Curcumin, we assessed T. gondii DNA concentrations in treated and untreated mice. Neither the amount of T. gondii DNA nor the number of parasitophorous vacuoles containing T. gondii tachyzoites in the ileum differed significantly between treated and Placebo groups at the same time point (data not shown).

**Immuno-modulatory effects of Simvastatin, Resveratrol or Curcumin treatment in the mucosa in situ during acute ileitis**

To further elucidate potential immuno-modulatory mechanisms by which the compounds under investigation exerted their beneficial effects, we assessed the number of several immune cell subsets in the ileal mucosa and submucosa of treated vs control mice with ileitis (Fig. 3 A–D). Because acute inflammation in T. gondii ileitis is T-cell driven and Th1 dominated [13], and there is strong evidence that regulatory T cells accumulate at inflamed tissue sites in IBD patients [16], we quantified CD3+ and FOXP3+ T cells in the ileum in situ by immunohistochemistry. Ileitis resulted in a significant accumulation of CD3+ cells within the ileum mucosa and submucosa (p<0.000001 vs naive mice) (Fig. 3 A). This increase of T lymphocytes, however, was significantly less pronounced in mice treated either with Resveratrol or Curcumin (p<0.05 vs. Placebo) (Fig. 3 A). Furthermore acute ileitis was accompanied by a 50% reduction of FOXP3+ T lymphocytes in the ileum on d8 p.i. (p<0.00001 as compared to non-infected, naive animals, Fig. 3 B). Most importantly, mice from either the Simvastatin, Resveratrol or Curcumin treatment group displayed 20–30% higher FOXP3+ cell numbers as compared to Placebo controls with ileitis on d8 p.i. (p<0.05-0.00001) (Fig. 3 B).
Given that neutrophilic granulocytes are important effector innate immune cells during acute ileitis development, we investigated the recruitment of myeloperoxidase-77 (MPO-77) cells in the small intestinal lamina propria of both treated and control mice in the acute phase of disease (Fig. 3 C). On d8 p.i., a more than 5-fold increase in MPO-77 cells was observed within the ileum of Placebo control animals compared to naive mice, which were non-infected and untreated (p < 0.005). However, Simvastatin, Resveratrol or Curcumin treated mice displayed 25–50% fewer MPO-77 cells as compared to Placebo controls (p < 0.05) (Fig. 3 C).

In addition, we evaluated cell proliferation and regeneration in ileal sections on d8 p.i. using Ki-67, an antibody that recognizes a nuclear cell proliferation-associated antigen expressed in all active stages of the cell cycle [17]. After T. gondii infection, Ki-677 cell numbers increased significantly as compared to naive mice (p < 0.00001) (Fig. 3 D). Mice treated with either Resveratrol or Curcumin, however, displayed 50% more Ki-677 cells than Simvastatin- or Placebo treated animals on d8 p.i. (p < 0.005).

Taken together, treatment with Simvastatin, Resveratrol or Curcumin modulates small intestinal immune cell responses during acute ileitis by decreasing CD3+ and MPO77 cell accumulation but increasing FOXP3+ and Ki-677 cell numbers.

Pro- and anti-inflammatory cytokine responses after peroral treatment of mice with acute ileitis

Given that treated mice were resistant to the development of T. gondii-induced ileitis compared to untreated mice but T. gondii DNA concentration in the ileum did not differ significantly between these groups, we hypothesized that differential pro-inflammatory cytokine expression profiles within the ilea, mesenteric lymph nodes (MLNs) or spleens might explain the reduced immunopathology observed after treatment with the compounds mentioned above at d8 p.i.

The analysis of mRNA in the ileum in situ revealed that IL-23p19 (p < 0.001), IFN-γ (p < 0.05), and TNF-α (p < 0.01) expressions were significantly down-regulated in Curcumin-treated mice at d8 p.i. as compared to untreated controls (Fig. 4 A), whereas Resveratrol treated animals exhibited lower IL-6 ileal mRNA expression (Fig. 4 B). In addition, IFN-γ (p < 0.05) and MCP-1 (p < 0.05) secretion into ex vivo ileum cultures were significantly lower after Resveratrol, Curcumin or Simvastatin treatment compared to Placebo (Fig. 5 A-B). Furthermore, significantly higher amounts of the anti-inflammatory cytokine IL-10 were found in the ilea (p < 0.01-0.001), MLNs (p < 0.01-0.005) and spleens (p < 0.05-0.01) after either treatment regimen compared to Placebo controls with ileitis (Fig. 6 A-C).

Taken together, our results show that treatment with either Simvastain, Resveratrol or Curcumin modulates the cytokine profile within the small intestine which agrees with changes of immune cell subsets (fewer T cells and neutrophils, more Tregs) observed in treated mice pointing towards less pro- and more anti-inflammatory responses.

Reduced pro-inflammatory gut bacterial species in the small intestine of mice treated with Simvastatin, Curcumin or Resveratrol

Because we have shown that E. coli overgrowth in the terminal ileum aggravates T. gondii induced inflammation [14,15], we compared the composition of the ileum microflora of mice after treatment with Simvastatin, Curcumin or Resveratrol at d8 p.i.. Cultural analysis demonstrated that the total bacterial load increased during ileitis, but was significantly reduced by 1 to 2 orders of magnitude in treated mice as compared to Placebo controls (Fig. 7 A) (p < 0.05-0.0005). A more detailed cultural analysis revealed that following treatment concentrations of pro-inflammatory bacterial species such as E. coli (Fig. 7 B) and enterococci (Fig. 7 C) were significantly reduced by 3.0 – 3.5 (p < 0.000001) and 1.0 – 1.5 (p < 0.0005) orders of magnitude, respectively, whereas the potentially anti-inflammatory lactobacilli and bifidobacteria populations were slightly increased by up to 1.0 log orders (Fig. 7 D) (p < 0.05-0.0005). Counts of Clostridium and Eubacterium spp. were unaffected after treatment (data not shown). Interestingly, changes in the ileal flora
composition were comparable in the respective treatment groups. Furthermore, a direct antimicrobial effect of Simvastatin, Resveratrol or Curcumin was ruled out by specific in vitro testing of the substances in the presence of the highly susceptible laboratory strain Bacillus subtilis (data not shown). Thus, shifts in bacterial ileal flora concentrations (lower bacterial loads and less E. coli overgrowth) in treated mice during ileitis were not due to direct antimicrobial effects but rather agrees with the observed macroscopic and microscopic anti-inflammatory effects of the respective substances.

Figure 3. Quantification of defined cell population in the ileum of mice in situ after treatment with Simvastain, Resveratrol or Curcumin (8 days after T. gondii infection). The average number of cells positive for (A) CD3, (B) FOXP3, (C) MPO7 (Myeloperoxidase), and (D) Ki-67 from at least six high power fields (HPF, 400× magnification) per animal were determined microscopically in immunostained ileum sections at d8 p.i. after treatment of mice with Placebo, Simvastain (SIMVA), Resveratrol (RESVE), or Curcumin (CURCU) from d-2 until d8 p.i., and naive, uninfected animals. Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least three independent experiments. doi:10.1371/journal.pone.0015099.g003
Figure 4. m-RNA Expression of pro-inflammatory cytokines in ilea of mice 8 days after T. gondii infection and treatment with (A) Curcumin or (B) Resveratrol from d-2 until d8 p.i. compared to Placebo controls. RT-PCR results of IL-23p19, IFN-γ and TNF-α (A) and IL-6 (B) expression from individual mice are expressed as fold changes relative to HPRT mRNA expression (arbitrary units). Numbers of analyzed animals are given in parentheses. Mean values and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least three independent experiments.

doi:10.1371/journal.pone.0015099.g004

Figure 5. (A) IFN-γ and (B) MCP-1 concentrations (CBA-ELISA) in supernatants of ileum cultures from naive, uninfected animals and mice treated with Simvastatin (SIMVA), Resveratrol (RESVE) or Curcumin (CURCU) from d-2 until d8 p.i. as compared to Placebo controls (8 days after T. gondii infection). Numbers of analyzed animals are given in parentheses. Mean values, standard errors of the mean, and significance levels as indicated were determined by the Student’s t test. Data are pooled from at least two independent experiments.

doi:10.1371/journal.pone.0015099.g005
Simvastatin, Curcumin or Resveratrol treatment prevents bacterial translocation during T. gondii-induced ileitis

Since we have recently demonstrated that acute ileitis is accompanied by translocation of living bacteria from the commensal gut flora into adjacent organs [15] we lastly investigated translocation rates following Resveratrol, Simvastatin, or Curcumin treatment. Bacterial translocation into MLNs was detected in all animals at day 8 p.i. (Fig. 8 A). Living bacteria translocated into the spleen in 78.1%, 57.1%, 55.6%, or 33.3% of cases after treatment with Placebo, Resveratrol, Simvastatin, or Curcumin, respectively (Fig. 8 B). The translocation rates into liver (Fig. 8 C) and kidney (Fig. 8 D) were much lower in Resveratrol (57.1% and 42.9%, respectively) and Simvastatin (55.6% and 22.2%, respectively) treated animals as compared to the Placebo (77.8% and 66.7%, respectively) and Curcumin (77.8% and 66.7%, respectively) groups. Oral treatment with Simvastatin (22.2%) or Curcumin (11.1%) resulted in less frequent (77.8% and 66.7%, respectively) groups. Oral treatment with Placebo (77.8% and 66.7%, respectively) and Simvastatin (55.6% and 22.2%, respectively) treated animals as compared to Resveratrol- (57.1% and 42.9%, respectively) and Curcumin- (55.6% and 22.2%, respectively) treated animals as compared to the Placebo (77.8% and 66.7%, respectively) and Simvastatin (77.8% and 66.7%, respectively) groups. Oral treatment with Simvastatin (22.2%) or Curcumin (11.1%) resulted in less frequent translocation rates following Resveratrol, Simvastatin, or Curcumin treatment. Living bacteria could be cultured from the respective organs of naïve (non-infected, untreated) mice with intact small intestinal barrier function.

Thus, Simvastatin, Curcumin and Resveratrol treatment remarkably reduced bacterial translocation into subepithelial tissues thereby minimizing bacteria/TLR ligation and preventing immune cell activation and subsequent inflammatory response initiation.

Discussion

Inflammatory bowel diseases (IBD) such as Crohn’s disease (also termed ileitis terminalis) and ulcerative colitis are characterized by chronic intestinal inflammation with acute episodes of multifactorial etiology [18,19]. The vast majority of experimental studies concerning intestinal inflammation have been performed in murine models affecting the colon. Thus, we used our well-established, hyper-acute model of small intestinal inflammation following T. gondii infection to investigate anti-inflammatory and immuno-modulatory effects of Resveratrol, Curcumin, and Simvastatin in ileal inflammation. The immunopathology observed after T. gondii infection is driven by Th1 cells and by the bacterial gut flora. This situation resembles immunopathology during acute episodes of Crohn’s disease [20]. Furthermore, the underlying immunopathology is characterized by an overproduction of pro-inflammatory cytokines such as IL-12, IFN-γ, TNF-α, and IL-23, a key regulator of the immune response cascade [12,13,21].

Here, we demonstrate that hyper-acute inflammation in the small intestine is ameliorated by either Resveratrol, Curcumin or Simvastatin treatment. In addition, the anti-inflammatory effects of the compounds under investigation during the acute phase of ileitis (on day 8 after ileitis induction by peroral infection with T. gondii) were comparable: animals from all three treatment groups were protected from immunopathology development and exhibited better clinical conditions, less body weight loss and shortening of the small intestinal length. Untreated mice also displayed severe pan-ileitis whereas treated animals (irrespective of the compound used) only showed minor mucosal changes with an intact epithelial lining. Furthermore, reduced ileal inflammation in Resveratrol and Curcumin treated mice might result from compensatory higher proliferation rates of intestinal epithelial cells found in the ileal mucosa as shown by higher Ki67+ cell numbers after respective treatment.

Moreover, the amelioration of immunopathology was accompanied by a reduced accumulation of CD3+ T lymphocytes as well as lower expression of the key regulator IL-23 and pro-inflammatory cytokines IFN-γ and TNF-α in the small intestinal lamina propria after Resveratrol or Curcumin treatment. Furthermore, ileal secretion of IFN-γ and the monocyte chemotactic protein MCP-1 was significantly decreased after treatment with Simvastatin, Resveratrol, or Curcumin. In parallel, myeloperoxidase-7+ neutrophilic granulocytes recruitment was diminished thereby limiting oxidative stress in the ileum and maintaining an integral epithelial cell barrier function. In addition, numbers of FOXP3+ cells were diminished in untreated mice, but significantly increased (comparable to the observed numbers in naïve mice) in treated animals after ileitis induction which correlates with increased concentrations of the anti-inflammatory cytokine IL-10 observed in ileum, MLNs, and spleen at d8 p.i.
Simvastatin has been shown to inhibit acute as well as chronic inflammatory responses in a cholesterol-independent manner by interfering with endothelial adhesion and leukocyte migration to sites of inflammation [11,22]. In rats with normal blood cholesterol levels, simvastatin was found to ameliorate immuno-pathology in an acute TNBS colitis model by blocking neutrophil accumulation in the small intestine and lowering serum TNF-α levels [23].

Curcumin exerts its anti-inflammatory effects in murine colitis models by inhibiting COX2- and pro-inflammatory cytokine expression such as nitric oxide [9,24,25] and suppressing NF-κB activation [26,27].
In acute TNBS rat colitis model, a decreased neutrophil influx and IL-1β production as well as an enhanced apoptosis of colonic mucosa was observed following Resveratrol treatment [28]. In chronic DSS-induced colitis, both decreased expression of pro-inflammatory cytokines (TNF-α, NO, and IL-1β) and increased anti-inflammatory mediators (IL-10) in the colonic mucosa contributed to attenuate inflammation after Resveratrol treatment [29]. In addition, even low dose Resveratrol treatment exerted anti-inflammatory effects in an acute DSS-induced colitis model by reducing expression levels of prostaglandin-E2, COX2, and NO [6].

Changes in commensal gut flora composition observed in acute T. gondii-induced ileitis resemble the gut flora changes found in humans with IBD [14,15]. Shifts in the ileal flora composition become overt around d5 p.i., the time point when first significant defects of the epithelial barrier are histologically detectable. Ileitis development is accompanied by decreased species diversity, decreased loads of potentially anti-inflammatory species such as lactobacilli and bifidobacteria and a marked increase in commensal, potentially pro-inflammatory E. coli in the ileum lumen by 6–8 orders of magnitude. Furthermore, overgrowing E. coli within the gut aggravates Toll-like receptor- (TLR-) 4 driven immune responses during T. gondii-induced ileitis [15]. In addition, overgrowing bacteria easily translocate through a disrupted epithelial cell barrier into the intestinal lamina propria, lymphoid tissues (e.g. the ileum draining MLNs) and subsequently come in contact with immune cells thereby exacerbating intestinal inflammation. Lastly, when translocating bacteria reach the systemic blood stream, peritonitis, sepsis and subsequent multiple organ failure occurs with fatal consequences [14,15]. Therefore, we investigated whether Simvastatin, Resveratrol or Curcumin could prevent gut flora composition changes and bacterial translocation after T. gondii infection. Interestingly, treatment with either compound significantly diminished total bacterial ileal burdens as compared to untreated animals. Strikingly, lower E. coli and enterococci counts were found in treated mice whereas lactobacilli and bifidobacteria populations were slightly but significantly increased. In addition, ileitis development is accompanied by a marked decrease in the lactobacilli and bifidobacteria populations [14] and strikingly, after either treatment these lactobacilli and bifidobacteria populations remained at comparable levels with naive, uninfected mice. Remarkably, none of the compounds had a direct anti-microbial effect in vitro.

Larrosa and co-workers reported in 2009 similar flora shifts in an acute DSS-induced colitis model, however, to a much lesser extent: After low-dose Resveratrol treatment, rats exhibited increases in lactobacilli and bifidobacteria populations within the colonic lumen and blocked the increase in enterobacteria (mainly E. coli) [6]. In several studies, a protective effect of lactobacilli and bifidobacteria in DSS-colitis could be demonstrated [30], as well as modulatory effects upon pro-inflammatory responses in intestinal epithelial cells that have been challenged with pathogenic enterobacteria [31]. Thus, abundance of anti-inflammatory lactobacilli and bifidobacteria together with scarcity of pro-inflammmatory E. coli and enterococci.
inflammatory *E. coli* markedly limit inflammation during *T. gondii* ileitis.

Resveratrol, Simvastatin, or Curcumin treatment might have an anti-inflammatory effect by directly interfering with the TLR/MyD88 signaling pathway. Recent findings in acute TNBS-induced colitis model in rats demonstrate that Curcumin-induced inhibition of intestinal inflammation involves TLR-4 and MyD88 [32].

Furthermore, an effect of Curcumin on matrixmetalloproteinases (MMPs; important in the pathogenesis of human IBD [33]) was recently described [34]: Curcumin down-regulated MMP-9 (gelatinase-B activity on inflammation-induced intestinal epithelial cells in vitro). We have recently shown that non-selective MMP- as well as selective gelatinase blockage by a synthetic compound ameliorated *T. gondii* ileitis [12]. However, MMP-2, but not MMP-9 played a crucial role in mediating small intestinal pathology. MMP-9 is proposed to play an important role in experimental colitis [35]. Interestingly, neutrophils have been proposed as an important source for MMPs. Thus, inhibition of neutrophil migration by the investigated compounds might also down-modulated MMP secretion thereby diminishing epithelial cell inflammation.

In a recent study, Curcumin has been shown to inhibit oxidative stress [36] that in turn has been associated with tight junction opening, thereby modifying intestinal permeability [37]. In the present study, bacterial translocation rates (due to compromised epithelial barrier function) into spleen and cardiac blood after treatment with either compound were lower as compared to the Placebo group. Therefore, Resveratrol, Simvastatin, and Curcumin might modulate tight junction protein expression and function.

Most strikingly, 20 to 40% of the animals treated with Resveratrol, Simvastatin, or Curcumin survived the acute phase of inflammation whereas all untreated mice had died at d11 p.i. In addition, 40% of Resveratrol treated mice displayed a long-term survival (until the end of the observation period until d19 p.i.; p<0.005 vs. Placebo). The long-term survival effect of Resveratrol is remarkable for three reasons: First, in our study, the duration of treatment (before and during course of acute inflammation) was rather short: Resveratrol treatment was initiated two days prior to ileitis induction and lasted 10 days in total; at d8 p.i. treatment was withdrawn. Second, given that the bioavailability of the compound is low, short-term and local rather than systemic effects are observed within the gut lumen (effective until d8/d9 p.i.). Because *T. gondii*-induced ileitis compromises the intestinal absorption capacity, Resveratrol absorption after oral application is also reduced. Third, Resveratrol treatment improves survival in a hyper-acute small intestinal inflammation model where all Placebo control mice died. Thus far, Resveratrol treatment has only been shown to reduce mortality in a chronic colitis model [29]. We might hypothesize that Resveratrol treatment prevents bacterial translocation into the systemic circulation because in our study, we did not observe bacterial growth in any of blood cultures drawn from Resveratrol treated mice. Therefore, mice are protected from a bacteremia-induced sepsis that leads to death. Furthermore, fewer bacteria translocation rates into sub-epithelial tissues might be due to a less compromised epithelial barrier function. Fewer translocation rates are mirrored by an IL-6 decrease in the ileum of Resveratrol treated animals. Our findings agree with those in the literature suggesting that genes belonging to the IL-6 pathway are down-regulated in Resveratrol treated mice in experimental colitis [6] and other inflammation models [38].

In conclusion, here we show for the first time that Resveratrol, Curcumin, and Simvastatin exert potent anti-inflammatory effects in a hyper-acute Th1-type driven small intestinal inflammation model. In addition, Resveratrol, Curcumin, and Simvastatin represent novel and promising intervention strategies for prophylaxis and therapy of small intestinal inflammation in IBD.

**Materials and Methods**

**Ethics Statement**

All animal experiments were conducted according to the German animal protection laws (LaGeSo Berlin, TVV G0145/10 and G0146/10) with approval from the Charité – Universitätsmedizin ethical committee. Animal welfare was monitored twice daily by assessment of clinical conditions and weight loss of mice.

**Mice, parasites and ileitis induction**

C57BL/10ScSn (wildtype) mice used for experiments were 3 months old and bred under specific pathogen-free (SPF) conditions in the Forschungsinstitut für Experimentelle Medizin (Charité, Berlin, Germany). For induction of ileitis, mice were infected orally with 100 *T. gondii* cysts (ME49 strain) from homogenized brains of intraperitoneally infected NMRI mice in a volume of 0.3 ml phosphate-buffered saline (PBS, pH 7.4) by gavage, as described previously [14].

**Compounds**

Resveratrol, Curcumin, and Simvastatin were dissolved in 2% Carboxy-Methyl-Cellulose (in PBS; all purchased from Sigma-Aldrich, München, Germany) and administered to mice with a daily dose of 20 mg, 100 mg, and 20 mg per kg body weight, respectively. Mice received the respective verum compound or the carrier solution (serving as Placebo control) perorally by gavage (in a 0.3 ml volume) once daily starting 2 days before *T. gondii* infection until the end of the experiment at day (d) 8 post infection (p.i.).

**Sampling procedures and determination of small intestinal shortening**

Mice were sacrificed by isoflurane 8 days after infection (Abbott, Wiesbaden, Germany). Cardiac blood and tissue samples from liver, spleen, kidneys, mesenteric lymph nodes and terminal ileum were removed under sterile conditions. Intestinal samples from each mouse were collected in parallel for histological, microbiological, immunological and molecular analyses. The relative shortening of the small intestine was calculated by dividing the difference of the mean length of small intestine from age- and sex-matched naïve control mice minus the length of infected mice at day 8 p.i. and then multiplied by 100 over the mean length of naïve control mice small intestines (relative shortening in length = (mean d0 – d8 p.i.)×100/mean d0). Results were expressed as % shortage.

**Histologic scores and determination of parasite load**

Histologic scores of ileitis and parasite loads were determined in tissue samples from terminal ileum immediately fixed in 5% formalin and embedded in paraffin as described earlier [14,15]. Sections (5 µm) were stained with hematoxylin and eosin and examined by light microscopy. Our standardized histological inflammation score ranging from 0 to 6 (0, normal; 1, edematous blubbing; 2, cell-free exudate into the lumen, but intact epithelium; 3, cellular shedding into the lumen; 4, beginning epithelial disintegration; 5, mucosal destruction <50% of small intestine length; 6, complete destruction >50% of small intestine length; 6, complete destruction >50% of small intestine length.
length, severe necroses) was used for blinded duplicate evaluation (by M.M.H. and M.M.). Numbers of parasitophorous vacuoles containing tachyzoites or tachyzoite antigens were determined by immunohistology using a rabbit anti-*T. gondii*-IgG antiserum and counted in the terminal ileum, as previously described [21]. In addition, *T. gondii* DNA in ileal biopsies was quantified as described earlier [12].

**Immunohistochemistry**

In situ immunohistochmeical analysis of ileum paraffin sections were performed as described previously [39]. Primary antibodies against CD3 (1:300; Dako, Glostrup, Denmark, dilution 1:10), FOXP3 (1:16, Bioscience, San Diego, USA, 1:100), myeloperoxidase-7 (1:300; Dako, 1:500), and Ki-67 (1:200; Dako, 1:100) were used. For each animal, the average number of positive stained cells within at least six independent high power fields (HPF, high power visual field in 400 x magnification) were determined microscopically by two independent investigators (M.M.H. and C.L.) and subjected to statistical analysis as indicated.

**Real-time PCR**

RNA was isolated from organs, reverse transcribed and analyzed as described previously [12]. Mouse IL-23p19, IFN-γ and TNF-α mRNA expressions were detected and analyzed using Light Cycler Data Analysis Software, Roche. Expression levels were calculated relative to the HPRT expression (and indicated as “Arbitrary Units”).

**Statistical analysis**

Mean values, medians, standard deviations, standard errors of the mean, and levels of significance were determined using appropriate tests as indicated (Student’s t-Test, Mann-Whitney U-Test or the log-rank test for Kaplan-Meier analysis of survival). Two-sided probability (p) values ≤ 0.05 were considered significant. All experiments were repeated at least twice.

**Acknowledgments**

The authors thank Michaela Waittord, Ursula Rüssendorf, Ines Puschendorf, Simone Speckermann, Gernot Reifenberger, Uwe Lohmann and the staff of the animal research facility for excellent technical assistance and Gunther Heimesaat for critical discussions.

**Author Contributions**

Conceived and designed the experiments: MMH AF SB. Performed the experiments: MMH MM AF RP BO L-MH SB. Analyzed the data: MMH MM AF RP BO L-MH AAK CL. Contributed reagents/materials/analysis tools: CL AAK. Wrote the paper: MMH MM AF RP BO L-MH MM AF RP BO L-MH AAK SB UBG.

**References**

1. Jain SK (1994) ethnobotany and research on medicinal plants in India. Ciba Found Symp 185: 153-164; discussion 164-150.
2. Kobashigawa JA, Katsnelson S, Lako H, Johnson JA, Yeatman L, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621–627.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lezin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
4. Emami N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol against CD3+ T cells in a T-cell dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with *Toxoplasma gondii*. J Immunol 177: 8785–8795.
5. Munoz M, Heimesaat MM, Damk K, Struck D, Lohmann U, et al. (2009) Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 206: 3047–3059.
6. Liesenfeld O, Kosek J, Remington JS, Suzuki Y (1996) Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Immunol 157: 6875–6879.
7. Diomede L, Albani D, Sottocorno M, Donati MB, Bionchi M, et al. (2001) In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21: 1372–1379.
8. Maul J, Heimesaat MM, Derendorf H, Lohmann U, et al. (2005) Peripheral exuberence of macrophages in rats with severe acute pancreatitis. Inflamm Res 54: 522–537.
9. Larrosa M, Vazquez-Gascón MJ, Selma MV, González-Sarrias A, Totti S, et al. (2005) Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 53: 2211–2220.
10. Simes J, Furbeg CD, Braunwald E, Davis BR, Ford I, et al. (2002) Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 23: 207–215.
11. Heimesaat MM, Fischer A, Jahn H, Niebergall J, Freudenberg M, et al. (2007) Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of bacterial lipopolysaccharide from commensal Escherichia coli. Gut 56: 941–948.
12. Kaiser K, Liesenfeld O, Kosek J, Remington JS, Suzuki Y (1996) Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with *Toxoplasma gondii*. J Exp Med 184: 597–607.
13. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, et al. (2006) Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with *Toxoplasma gondii*. J Immunol 177: 8755–8759.
14. Cai Y, Lu R, Bruns A, Heimesaat MM, Derendorf H, et al. (2007) Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 56: 941–948.
15. Maud J, Loddinensen C, Mundt P, Berg E, Giese T, et al. (2005) Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 130: 1808–1818.
16. Gerdes J, Li L, Schluter C, Ducharow M, Wohlenberg C, et al. (1991) Immunobiochemismal and molecular biologic characterization of the cell...
proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867–873.

18. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429.

19. Basset C, Holton J (2002) Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog 85: 53–56.

20. Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 183 Suppl 1: S86–101.

21. Vossenkamer A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, et al. (2004) Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 34: 3197–3207.

22. Mahé BM, Dhonnchu TN, Burke JP, Sow A, Wood AE, et al. (2009) Statins alter neutrophil migration by modulating cellular Rho activity—a potential mechanism for statins-mediated pleotropic effects. J Leukoc Biol 85: 186–193.

23. Jahan N, Gekki N, Erkan F, Sirvanci S, Yuksel M, et al. (2006) Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol 41: 954–962.

24. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, et al. (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333–342.

25. Ung VY, Foshaug RR, MacFarlane SM, Churchill TA, Doyle JS, et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci 55: 1272–1277.

26. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al. (1999) Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity. J Immunol 163: 3474–3483.

27. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, et al. (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747–1752.

28. Martin AR, Villegas I, La Casa C, de la Lastra CA (2004) Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 67: 1309–1410.

29. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA (2009) Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633: 78–84.

30. Fooks LJ, Gibson GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 89 Suppl 1: S39–49.

31. Candela M, Perna F, Carnevali P, Vitali B, Giatto R, et al. (2008) Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 125: 286–292.

32. Lubbad A, Orióvos MA, Khan I (2009) Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127–135.

33. Basset C, Holton J (2002) Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog 85: 33–56.

34. Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 183 Suppl 1: S86–101.

35. Vossenkamer A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, et al. (2004) Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 34: 3197–3207.

36. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al. (1999) Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity. J Immunol 163: 3474–3483.

37. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, et al. (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747–1752.

38. Kouri TT, Gaet JA, Fogazii H, Hofmann W, Hallander HO, et al. (2000) Towards European urinalysis guidelines: Introduction of a project under European Confederation of Laboratory Medicine. Clin Chim Acta 297: 305–311.

39. Martin AR, Villegas I, La Casa C, de la Lastra CA (2004) Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 67: 1309–1410.

40. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA (2009) Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633: 78–84.

41. Fooks LJ, Gibson GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 89 Suppl 1: S39–49.

42. Candela M, Perna F, Carnevali P, Vitali B, Giatto R, et al. (2008) Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 125: 286–292.

43. Lubbad A, Oriowo MA, Khan I (2009) Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127–135.

44. Basset C, Holton J (2002) Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog 85: 33–56.

45. Liesenfeld O (2002) Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease? J Infect Dis 183 Suppl 1: S86–101.

46. Vossenkamer A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, et al. (2004) Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 34: 3197–3207.

47. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al. (1999) Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappaB kinase activity. J Immunol 163: 3474–3483.

48. Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, et al. (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11: 1747–1752.

49. Martin AR, Villegas I, La Casa C, de la Lastra CA (2004) Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 67: 1309–1410.

50. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, de la Lastra CA (2009) Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633: 78–84.

51. Fooks LJ, Gibson GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 89 Suppl 1: S39–49.